Human epidermal growth factor receptor‐2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis

Cancer Science

Xiangjiao Meng¹  Renben Wang³  Zhaoqin Huang⁴  Jianbo Zhang²  Rui Feng³  Xiaoqing Xu³  Kunli Zhu³  Xue Dou³  Dong Chen³ 

[1]Medical School of Shandong University, Jinan, China

[2]Department of Pathology of Shandong Cancer Hospital and Institute, Jinan, China

[3]Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China

[4]Department of Radiology Provincial Hospital Affiliated to Shandong University, Jinan, China

关键词: HER‐2;    neoadjuvant chemoradiotherapy;    rectal cancer;    survival;    tumor response;   

DOI  :  10.1111/cas.12421

来源: Wiley

【 摘 要 】

Abstract

The aim of this study was to determine whether pretreatment status of human epidermal growth factor receptor-2 (HER-2) could predict pathologic response to neoadjuvant chemoradiotherapy (nCRT) and outcomes for patients with locally advanced rectal cancer (LARC). A total of 119 patients diagnosed with LARC received standardized multimodal treatment. Their HER-2 status was determined in pretreatment biopsies by immunohistochemistry (IHC) and FISH. Tumor response was assessed in resected regimens using the tumor regression grade system and TNM staging system. Twenty-two cases in 119 patients assessed as IHC3+ or IHC2+ plus gene-amplified were determined as HER-2 positive. Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05). HER-2 status could not predict pathologic response to nCRT based on downstaging (P = 0.210) and tumor regression grade (P = 0.085) but it provides us with a trend that HER-2-positive tumors may be resistant to nCRT. Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026). It can act as a worse prognostic factor for LARC patients.

【 授权许可】

CC BY-NC-ND   
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.